Tr1X

Tr1X Aims to Develop Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases. Tr1X's pipeline is primarily based on the work of its scientific founder, Dr. Maria Grazia Roncarolo, the discoverer of Type 1 Regulatory T (Tr1) cells. Tr1 cells are a subset differentiated from regulatory T cells and are crucial for maintaining immune balance and tolerance in healthy individuals. These cells have been observed to exhibit several important functions in preclinical models and patients, including suppressing local inflammation and downregulating inflammasomes, inhibiting pathogenic effector T-cell responses, and inducing long-term tolerance.